Healthcare
Fresenius SE & Co. KGaA(FSNUF)
Live Price
Offline$54.35
+0.00% today
1Y Change
+8.07%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $22.47B
- Revenue Growth
- +4.7%
- EPS Growth
- +167.9%
- Dividend Yield
- 2.5%
Coverage: 247 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fresenius SE & Co. KGaA (FSNUF) is a Healthcare stock with a market cap of $22.47B and listed on OTC. The stock last traded around $54.35 and up 8.1% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of +4.7%, EPS growth of +167.9%, a dividend yield of 2.5%. What stands out right now is revenue +4.7%, EPS +167.9%, free cash flow -21.4% with operating margin 9.5% and ROIC 4.6%. The dividend matters to the case here, with a current yield around 2.5%. Valuation is more restrained than many high-expectation growth names at P/E 17.8 and price/sales 1.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines FSNUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.7% vs +7.6% peer median
Operating Margin
Below sector median
+9.5% vs +19.4% peer median
P/E
Below sector median
17.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.7% and EPS at +167.9%, with operating margin around 9.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | β | +0.0% | +0.0% | +0.0% |
2026 Feb 25, 2026 | -15.2% | +0.0% | -2.8% | -2.8% |
2025 Nov 4, 2025 | -14.3% | +0.0% | +2.8% | -3.5% |
Benchmark Edge
FSNUF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FSNUF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FSNUF Max Drawdown
-10.78%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FSNUF and SPY.
Company Overview
Fresenius SE & Co. KGaA
Other OTC
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HΓΆhe, Germany.
- Leadership
- Michael Sen
- IPO Date
- Mar 14, 2012
- Employees
- 175.2k
- Street Address
- Else-Kroener-Strasse 1
- Mailing
- Bad Homburg vor der HΓΆhe, 61352
- Region
- Bad Homburg vor der HΓΆhe, DE
- Reporting Currency
- USD
- Investor Line
- 49 6172 608 2487
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 17.8
- EV/EBITDA
- 10.0
- Price/Sales
- 1.0
- Price/Book
- 1.2
Growth
- Revenue
- +4.7%
- EPS
- +167.9%
- Free Cash Flow
- -21.4%
Profitability
- Gross Margin
- 24.9%
- Operating Margin
- 9.5%
- Net Margin
- 5.5%
- ROE
- 6.7%
- ROIC
- 4.6%
Balance Sheet
- Debt/Equity
- 0.62
- Current Ratio
- 1.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.